
## Christopher J O'donnell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7662151/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Synthetic Approaches to the New Drugs Approved During 2020. Journal of Medicinal Chemistry, 2022, 65, 9607-9661.	6.4	18
2	Development of Highly Optimized Antibody–Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia. Clinical Cancer Research, 2021, 27, 622-631.	7.0	11
3	Synthetic Approaches to the New Drugs Approved during 2019. Journal of Medicinal Chemistry, 2021, 64, 3604-3657.	6.4	30
4	NOTCH3-targeted antibody drug conjugates regress tumors by inducing apoptosis in receptor cells and through transendocytosis into ligand cells. Cell Reports Medicine, 2021, 2, 100279.	6.5	7
5	PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers. Molecular Cancer Therapeutics, 2020, 19, 2068-2078.	4.1	32
6	Synthetic Approaches to New Drugs Approved during 2018. Journal of Medicinal Chemistry, 2020, 63, 10652-10704.	6.4	33
7	Synthetic Approaches to the New Drugs Approved During 2017. Journal of Medicinal Chemistry, 2019, 62, 7340-7382.	6.4	44
8	Novel PIKK inhibitor antibody-drug conjugates: Synthesis and anti-tumor activity. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 943-947.	2.2	6
9	CXI Dimers as Antibody–Drug Conjugate (ADC) Payloads. RSC Drug Discovery Series, 2019, , 209-240.	0.3	2
10	Synthetic Approaches to New Drugs Approved During 2016. Journal of Medicinal Chemistry, 2018, 61, 7004-7031.	6.4	58
11	Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate. Journal of Medicinal Chemistry, 2018, 61, 1001-1018.	6.4	23
12	Kinetically guided radical-based synthesis of C(sp <sup>3</sup> )â^'C(sp <sup>3</sup> ) linkages on DNA. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E6404-E6410.	7.1	124
13	Synthetic Approaches to the New Drugs Approved During 2015. Journal of Medicinal Chemistry, 2017, 60, 6480-6515.	6.4	103
14	Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug Conjugates. AAPS Journal, 2017, 19, 1123-1135.	4.4	51
15	Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugate. PLoS ONE, 2017, 12, e0178452.	2.5	24
16	RN927C, a Site-Specific Trop-2 Antibody–Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models. Molecular Cancer Therapeutics, 2016, 15, 2698-2708.	4.1	78
17	Development of Solid-Phase Site-Specific Conjugation and Its Application toward Generation of Dual Labeled Antibody and Fab Drug Conjugates. Bioconjugate Chemistry, 2016, 27, 1030-1039.	3.6	50
18	Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design. Molecular Cancer Therapeutics, 2016, 15, 958-970.	4.1	141

Christopher J O'donnell

#	Article	IF	CITATIONS
19	Synthetic approaches to the 2014 new drugs. Bioorganic and Medicinal Chemistry, 2016, 24, 1937-1980.	3.0	84
20	Synthetic approaches to the 2013 new drugs. Bioorganic and Medicinal Chemistry, 2015, 23, 1895-1922.	3.0	63
21	Novel Anti-TM4SF1 Antibody–Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature. Molecular Cancer Therapeutics, 2015, 14, 1868-1876.	4.1	31
22	The Discovery and Characterization of the α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Potentiator <i>N</i> -{(3 <i>S</i> ,4 <i>S</i> )-4-[4-(5-Cyano-2-thienyl)phenoxy]tetrahydrofuran-3-yl}propane-2-sulfonamide (PF-04958242). Journal of Medicinal Chemistry, 2015, 58, 4291-4308.	6.4	23
23	Spliceostatin hemiketal biosynthesis in <i>Burkholderia</i> spp. is catalyzed by an iron/α-ketoglutarate–dependent dioxygenase. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E3376-85.	7.1	55
24	Discovery of Cytotoxic Dolastatin 10 Analogues with N-Terminal Modifications. Journal of Medicinal Chemistry, 2014, 57, 10527-10543.	6.4	118
25	Synthetic approaches to the 2012 new drugs. Bioorganic and Medicinal Chemistry, 2014, 22, 2005-2032.	3.0	40
26	Synthetic approaches to the 2011 new drugs. Bioorganic and Medicinal Chemistry, 2013, 21, 2795-2825.	3.0	80
27	Synthetic approaches to the 2010 new drugs. Bioorganic and Medicinal Chemistry, 2012, 20, 1155-1174.	3.0	59
28	Synthetic approaches to the 2009 new drugs. Bioorganic and Medicinal Chemistry, 2011, 19, 1136-1154.	3.0	76
29	Discovery of 4-(5-Methyloxazolo[4,5- <i>b</i> ]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a Novel α7 Nicotinic Acetylcholine Receptor Agonist for the Treatment of Cognitive Disorders in Schizophrenia: Synthesis, SAR Development, and in Vivo Efficacy in Cognition Models. Journal of Medicinal Chemistry, 2010, 53, 1222-1237.	6.4	68
30	Synthetic Approaches to the 2008 New Drugs. Mini-Reviews in Medicinal Chemistry, 2009, 9, 1655-1675.	2.4	23
31	Synthesis and SAR studies of 1,4-diazabicyclo[3.2.2]nonane phenyl carbamates – subtype selective, high affinity α7 nicotinic acetylcholine receptor agonists. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 4747-4751.	2.2	14
32	Synthetic Approaches to the 2007 New Drugs. Mini-Reviews in Medicinal Chemistry, 2008, 8, 1526-1548.	2.4	21